This study is open to adults with different types of advanced cancer (solid tumors). The
purpose of this study is to find out the most suitable dose of BI 907828 the participants can
tolerate. The most suitable dose is used in the second part to find out whether BI 907828
makes tumors shrink.
In this study, BI 907828 is given to humans for the first time. BI 907828 is a so-called MDM2
inhibitor that is being developed to treat cancer. BI 907828 is taken as a tablet.
Participants either take a dose of BI 907828 on one day every 3 weeks or on two days every 4
The participants are in the study for as long as they benefit from and can tolerate
treatment. The doctors regularly check the participants' general health during the study.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.